Advertisement |
|
Is your research limited by detection of CNS biomarkers in blood?
Learn how ultra-sensitive immunoassays can expand your access to the biology of the brain.
Register now for a free webinar "Novel CNS Biomarker Applications Enabled by Simoa Technology: Tau in Pre-Clinical & Clinical Studies."
December 2, 11 AM EST | |
|
|
|
|
|
TABLE OF CONTENTS |
|
|
December 2016 Volume 12 Number 12 | Advertisement
|
2015 2-year Impact Factor 18.418 Journal Metrics 2-year Median 13 | In this issue Comment Research Highlights News and Views Reviews Consensus Statement Perspectives
Also this month Featured article: The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative Pascal Sati, Jiwon Oh, R. Todd Constable, Nikos Evangelou, Charles R. G. Guttmann, Roland G. Henry, Eric C. Klawiter, Caterina Mainero, Luca Massacesi, Henry McFarland, Flavia Nelson, Daniel Ontaneda, Alexander Rauscher, William D. Rooney, Amal P. R. Samaraweera, Russell T. Shinohara, Raymond A. Sobel, Andrew J. Solomon, Constantina A. Treaba, Jens Wuerfel, Robert Zivadinov, Nancy L. Sicotte, Daniel Pelletier, Daniel S. Reich & on behalf of the NAIMS Cooperative |
|
|
|
|
|
Advertisement |
|
|
|
|
Advertisement |
|
Poster on Molecular mechanisms of amyotrophic lateral sclerosis
This poster from Nature Reviews Neuroscience provides an overview of the molecular and cellular mechanisms that have been proposed to contribute to the pathogenesis of amyotrophic lateral sclerosis, which is the most common form of motor neuron disease.
Download free online
Funded by a grant from MT Pharma America, Inc | |
|
|
|
|
Advertisement |
|
Translational Psychiatry is an online-only, open access journal exploring the translational pathway between research in neuroscience and conceptually novel treatments.
Explore the benefits of submitting your next research article. | |
|
|
|
|
COMMENT
| Top |
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line James J. Dowling Published online: 18 November 2016 p675 | doi:10.1038/nrneurol.2016.180 New therapies are much needed for Duchenne muscular dystrophy. Recent data from a phase II clinical trial has led to accelerated FDA approval of the exon-skipping drug eteplirsen. This approval is provisional, pending results of an ongoing phase III clinical trial, and came after much debate. Full Text | PDF
|
| | | | | | NEWS AND VIEWS
| Top | Cerebrovascular disease: Lobar cerebral microbleeds signal early cognitive impairment Yusuke Yakushiji & David J. Werring Published online: 18 November 2016 p680 | doi:10.1038/nrneurol.2016.179 A cross-sectional community-based study shows that strictly lobar cerebral microbleeds are associated with cognitive impairment, and might be a surrogate marker for early small-vessel injury. The anatomical distribution of cerebral microbleeds suggests that cerebral amyloid angiopathy (with or without Alzheimer disease) might have a key role in early cognitive impairment. Full Text | PDF
| CNS Infections: A new herpes zoster subunit vaccine for older adults Charlotte Warren-Gash & Judith Breuer Published online: 11 November 2016 p682 | doi:10.1038/nrneurol.2016.168 A randomized placebo-controlled phase III trial of adjuvanted herpes zoster subunit vaccine has shown a substantial improvement in vaccine efficacy in adults aged ≥70 years compared with the currently used, live attenuated vaccine. The finding has profound implications for reducing illness burden, although the duration of vaccine protection needs further evaluation. Full Text | PDF
| Advertisement | | Nature Outlook: Parkinson's disease
It is 200 years since Parkinson's disease was first described. This Outlook charts the progress of research in an engaging timeline and shows how our understanding of Parkinson's motor and non-motor symptoms has evolved. It also reveals the exciting new applications of smartphones in monitoring the disease.
Access the Outlook free online | |
|
| | | | | | REVIEWS
| Top | Neuroinflammation — using big data to inform clinical practice Calliope A. Dendrou, Gil McVean & Lars Fugger Published online: 18 November 2016 p685 | doi:10.1038/nrneurol.2016.171 Neuroinflammation is central in many neurological conditions, and 'big data' have the potential to elucidate the complexity of inflammatory processes. This Review considers how the drive to collect and analyse big data is increasing our understanding of neuroinflammation in disease, and how these data can be used to improve clinical management. Abstract | Full Text | PDF
| Unruptured intracranial aneurysms: development, rupture and preventive management Nima Etminan & Gabriel J. Rinkel Published online: 03 November 2016 p699 | doi:10.1038/nrneurol.2016.150 Unruptured intracranial aneurysms (UIAs) have a prevalence of 3% in the adult population. Currently, there is a large variability in how patients with UIAs are managed. Here, the authors review the latest human data on the formation, progression and rupture of intracranial aneurysms, as well the risks associated with preventive treatment. Abstract | Full Text | PDF
| | | CONSENSUS STATEMENT
| Top | The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative OPEN Pascal Sati, Jiwon Oh, R. Todd Constable, Nikos Evangelou, Charles R. G. Guttmann, Roland G. Henry, Eric C. Klawiter, Caterina Mainero, Luca Massacesi, Henry McFarland, Flavia Nelson, Daniel Ontaneda, Alexander Rauscher, William D. Rooney, Amal P. R. Samaraweera, Russell T. Shinohara, Raymond A. Sobel, Andrew J. Solomon, Constantina A. Treaba, Jens Wuerfel, Robert Zivadinov, Nancy L. Sicotte, Daniel Pelletier, Daniel S. Reich & on behalf of the NAIMS Cooperative Published online: 11 November 2016 p714 | doi:10.1038/nrneurol.2016.166 The central vein sign (CVS) has been proposed as a novel MRI biomarker to improve the accuracy and speed of multiple sclerosis (MS) diagnosis. This Consensus Statement from the NAIMS Cooperative provides a roadmap to help radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS. Abstract | Full Text | PDF
| | | | PERSPECTIVES
| Top | TIMELINE Article series: Peripheral neuropathies Guillain-Barré syndrome: a century of progress John A. Goodfellow & Hugh J. Willison Published online: 18 November 2016 p723 | doi:10.1038/nrneurol.2016.172 2016 has marked 100 years since the landmark description of what we now know as Guillain-Barré syndrome (GBS). Goodfellow and Willison chart the great progress we have made in understanding the pathogenesis of GBS, and developing established and emerging therapies. Abstract | Full Text | PDF
| OPINION Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification Ingmar Blümcke, Eleonora Aronica, Albert Becker, David Capper, Roland Coras, Mrinalini Honavar, Thomas S. Jacques, Katja Kobow, Hajime Miyata, Angelika Mühlebner, José Pimentel, Figen SöylemezoÄŸlu & Maria Thom Published online: 18 November 2016 p732 | doi:10.1038/nrneurol.2016.173 The recently revised 5th edition of the WHO classification of brain tumours 'blue book' will have a major impact in stratifying diagnosis and treatment. However, low-grade neuroepithelial tumours (LEATs), which present with early-onset focal epilepsy, lack integrated clinicopathological and molecular genetic diagnostic tools. The Neuropathology Task Force of the International League against Epilepsy will critically discuss this issue, as well as offer perspectives on how to decipher and validate clinically meaningful LEAT entities using the current WHO approach. Abstract | Full Text | PDF | Supplementary information
| | | Advertisement | | nature.com webcasts
Watch the free webinar available on-demand:
INNOVATING FOR OPHTHALMIC DISEASES Presented by BioPharma Dealmakers
Get the latest on innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.
REGISTER FOR FREE
Sponsored by: HEALIOS K.K. | Apellis | Mannin Research | |
|
| | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | |
|
Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.
|
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
|
|
No comments:
Post a Comment
Keep a civil tongue.